Douglas Amare, MD
Nephrology · Mobile, ALNPI 1265418883
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.0%), food and beverage and education — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 42.3% of the total. Reporting peaked in 2021 at $4,332 and has fallen 77.6% since, to $969 in 2025.
Across 218 payments — averaging $47.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$4K
- Amgen$3K
- Akebia Therapeutics Inc$367
- Vifor Pharma, Inc.$357
- Bayer$334
- Novartis$236
- plus $2K from 18 others
What the payments were for
- Speaking & faculty fees$5,56754%
- Food & beverage$4,71346%
- Education$340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 29 | $4,358 |
| Amgen(2 entities) | 66 | $3,073 |
| Akebia Therapeutics Inc | 18 | $367 |
| Vifor Pharma, Inc. | 21 | $357 |
| Bayer | 14 | $334 |
| Novartis | 8 | $236 |
| AstraZeneca | 13 | $229 |
| Travere Therapeutics, Inc. | 8 | $214 |
| Nxstage Medical, Inc. | 2 | $180 |
| Aurinia Pharma U.S., Inc. | 5 | $176 |
| OPKO Pharmaceuticals, LLC | 10 | $147 |
| Alnylam Pharmaceuticals Inc. | 1 | $120 |
| Calliditas Therapeutics US Inc. | 4 | $109 |
| Boehringer Ingelheim | 5 | $108 |
| Mallinckrodt Hospital Products Inc. | 3 | $75 |
| GSK | 3 | $59 |
| ANI Pharmaceuticals, Inc. | 1 | $30 |
| Fresenius USA Marketing, Inc. | 1 | $25 |
| Ardelyx, Inc. | 1 | $24 |
| Mozarc Medical US LLC | 1 | $23 |
| Lilly USA, LLC | 1 | $20 |
| Abbott | 1 | $20 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,314 in reported general payments places this provider in the 85th percentile of 164 nephrology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AuryxiaFerric Citrate | 44 | $129,331 |
| FarxigaDapagliflozin Propanediol | 78 | $59,963 |
| LokelmaSodium Zirconium Cyclosilicate | 22 | $18,436 |
| KerendiaFinerenone | 19 | $15,537 |
| Sevelamer Carbonate | 85 | $13,573 |
| RayaldeeCalcifediol | 13 | $13,502 |
| Lanthanum Carbonate | 12 | $13,134 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 13 | $1,265 |
| Furosemide | 181 | $1,183 |
| Potassium Citrate ErPotassium Citrate | 29 | $1,161 |
| Midodrine Hcl | 12 | $967 |
| Doxazosin Mesylate | 66 | $926 |
| Mycophenolate Mofetil | 11 | $900 |
| Losartan Potassium | 80 | $758 |
| Calcitriol | 25 | $554 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Akebia Therapeutics IncAuryxia | $367 | $129,33144 claims |
| AstraZenecaFarxiga, Lokelma | $229 | $78,400100 claims |
| BayerKerendia | $334 | $15,53719 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $147 | $13,50213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 164 nephrology providers in Alabama.
Other nephrology in Mobile
- Michael KleinmannMobile$50K
- Andrew FelisMobile$35K
- Roy CulpepperMobile$5K
- Purnima TripathyMobile$5K
- Christopher MireMobile$5K
- Richard MeadorMobile$4K
- John NipperMobile$4K
- Errol CrookMobile$4K
- Stephen WilberMobile$4K
- Michael QuadriniHuntsville$323K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.